Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
| CAPS Rating |
|
|---|---|
| Open | $1.20 |
| Previous Close | $1.20 |
| Daily Range | $1.15 - $1.25 |
| 52-Week Range | $0.95 - $3.10 |
| Market Cap | $33.16M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 17,400 |
| Average Daily Volume | 0 |
IDRA
VS S&P 500 (SPY)
This ticker is not currently Ratable.
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
IDRA Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
IDRA News and Commentary
- Idera: FDA Orders Hold On Midstage Trial Of Psoriasis Treatment – SmartMoney
- Idera Pharma Postpones Phase 2 Trial of Hepatitis C Treatment – SmartMoney
- GBMB update – Blog at The Motley Fool
- Nouveau Riche – Blog at The Motley Fool
- 15 Biotech Stocks With the Lowest Put/Call Ratios – SeekingAlpha
- Two IPOs Brave the Markets, Two Enter the Queue: Biotech's Latest Deals – SeekingAlpha
- Fresh bottoms for the grabbing – Blog at The Motley Fool
Related News and Articles
- Illuminating the Way Forward for Genomics – The Motley Fool
- When Passing Your Clinical Trial Isn't Enough – The Motley Fool
- This Just In: More Upgrades and Downgrades – The Motley Fool
- Life Technologies' Sequence of Success – The Motley Fool
- Is Avanir Pharmaceuticals the Perfect Stock? – The Motley Fool
- Can Amgen Convince Docs to Recommend Approval? – The Motley Fool
- Why Did My Stock Just Die? – The Motley Fool
- Curing Diseases Makes For a Bad Business Model – The Motley Fool
- Idenix Pharmaceuticals Shares Dropped: What You Need to Know – The Motley Fool
- What's Going on With These Biotech Stocks? – The Motley Fool
- Gilead Sciences Shares Surged: What You Need to Know – The Motley Fool
RSS Headlines
Fool UK
